Rebeca Mejias completed her Ph.D. in Cellular and Molecular Biology at the University of Seville, Spain, in 2006. She carried out her postdoctoral training at the Johns Hopkins University, Baltimore, USA. During this period, her studies focused on the molecular mechanisms causing Parkinson´s disease and autism spectrum disorders. She rejoined the University of Seville as a lecturer in physiology in 2015. In 2019, she moved to the U.K. to work at the company Abcam, plc. as a research area lead for neuroscience. She also worked as a senior researcher at the University of East Anglia, U.K., on a project focused on developing a library of mutants for the cyanobacterium Synechocystis. She is currently a senior lecturer at the University of Seville, where she studies the role of protein palmitoylation in dopaminergic disorders.
Rebeca Mejias completed her Ph.D. in Cellular and Molecular Biology at the University of Seville, Spain, in 2006. She carried out her postdoctoral training at the Johns Hopkins University, Baltimore, USA. During this period, her studies focused on the molecular mechanisms causing Parkinson´s disease and autism spectrum disorders. She rejoined the University of Seville as a lecturer in physiology in 2015. In 2019, she moved to the U.K. to work at the company Abcam, plc. as a research area lead for neuroscience. She also worked as a senior researcher at the University of East Anglia, U.K., on a project focused on developing a library of mutants for the cyanobacterium Synechocystis. She is currently a senior lecturer at the University of Seville, where she studies the role of protein palmitoylation in dopaminergic disorders.